Combinatorial pharmacodynamics of ceftolozane-tazobactam against genotypically defined β-lactamase-producing Escherichia coli: Insights into the pharmacokinetics/pharmacodynamics of β-lactam-P-lactamase inhibitor combinations

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 1967-1973

  Soon, Rachel L ^a,c   Lenhard, Justin R ^a   Bulman, Zackery P ^a   Holden, Patricia N ^a   Kelchlin, Pamela ^a   Steenbergen, Judith N ^b,d   Friedrich, Lawrence V ^b   Forrest, Alan ^a,e   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d Institute of Clinical Microbiology and Antibiotic Development   (United States)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CMY 10; BETA LACTAMASE CTX 15; BETA LACTAMASE CTX M; CEFTOLOZANE; TAZOBACTAM; UNCLASSIFIED DRUG; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA-LACTAMASE CTX-M-15; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; CMY-10 BETA-LACTAMASE; PENICILLANIC ACID;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; EC50; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; GENE EXPRESSION; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PENICILLANIC ACID;

EID: 84963600221     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02635-15     Document Type: Article

References (37)

1. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. 2007. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51:826-830. http://dx.doi.org/10.1128/AAC00860-06.
2. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. 2007. Stability of FR264205 against AmpC beta lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents 30:443-445. http://dx.doi.org/10.1016/j.ijantimicag.2007.05.019.
3. Zamorano L, Juan C, Fernandez-Olmos A, Ge Y, Canton R, Oliver A. 2009. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect 16:1482-1487.
4. Ambler RP, Meadway RJ. 1969. Chemical structure of bacterial penicillinases. Nature 222:24-26. http://dx.doi.org/10.1038/222024a0.
5. MoyaB, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101(FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 54:1213-1217. http://dx.doi.org/10.1128/AAC.01104-09.
6. Giske CG, Ge J, Nordmann P. 2009. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother 64:430-431. http://dx.doi.org/10.1093/jac/dkp193.
7. Livermore DM, Mushtaq S, Ge Y, Warner M. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 34:402-406. http://dx.doi.org/10.1016/j.ijantimicag.2009.03.021.
8. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus betalactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65:1972-1974. http://dx.doi.org/10.1093/jac/dkq248.
9. Cubist Pharmaceuticals. 2014. Zerbaxa (ceftolozane/tazobactam) for injection, for intravenous use. Cubist Pharmaceuticals, Lexington, MA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206829lbl.pdf
10. VanScoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG. 2013. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 57:4134-4138. http://dx.doi.org/10.1128/AAC.00461-13.
11. VanScoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of [3-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 57:5924-5930. http://dx.doi.org/10.1128/AAC.00656-13.
12. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809-2814. http://dx.doi.org/10.1128/AAC02513-12.
13. Gloede J, Scheerans C, Derendorf H, Kloft C. 2010. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother 65:186-201. http://dx.doi.org/10.1093/jac/dkp434.
14. Clinical Laboratory and Standards Institute (CLSI). 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S21. Clinical Laboratory and Standards Institute, Wayne, PA.
15. Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 52:1533-1537. http://dx.doi.org/10.1128/AAC.01254-07.
16. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob Agents Chemother 54:3427-3431. http://dx.doi.org/10.1128/AAC.01753-09.
17. Tsuji BT, Harigaya Y, Lesse AJ, Sakoulas G, Mylotte JM. 2009. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diagn Microbiol Infect Dis 64:220-224. http://dx.doi.org/10.1016/j.diagmicrobio.2009.01.028.
18. Riera E, Macia MD, Mena A, Mulet X, Perez JL, Ge Y, Oliver A. 2010. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 65:1399-1404. http://dx.doi.org/10.1093/jac/dkq143.
19. Bulik CC, Christensen H, Nicolau DP. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother 54:557-559. http://dx.doi.org/10.1128/AAC.00912-09.
20. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70:137-141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.004.
21. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160-201. http://dx.doi.org/10.1128/CMR.00037-09.
22. López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A. 2010. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamaseproducing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 16:132-136. http://dx.doi.org/10.1111/j.1469-0691.2009.02893.x.
23. Nannini EC, Stryjewski ME, Singh KV, Rude TH, Corey GR, Fowler VG, Jr, Murray BE. 2010. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 54:2206-2208. http://dx.doi.org/10.1128/AAC.01325-09.
24. Robin F, Krebs M, Delmas J, Gibold L, Mirande C, Bonnet R. 2011. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM-and complex mutant TEM-producing clinical strains of Escherichia coli. J Antimicrob Chemother 66:1052-1056. http://dx.doi.org/10.1093/jac/dkr045.
25. Craig WA, Bhavnani SM, Ambrose PG. 2004. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 50:229-230. http://dx.doi.org/10.1016/j.diagmicrobio.2004.07.006.
26. Anderl JN, Zahller J, Roe F, Stewart PS. 2003. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniaebiofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 47:1251-1256. http://dx.doi.org/10.1128/AAC.47.4.1251-1256.2003.
27. Waxman DJ, Strominger JL. 1983. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem 52:825-869. http://dx.doi.org/10.1146/annurev. bi.52.070183.004141.
28. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 56:544-549. http://dx.doi.org/10.1128/AAC.01752-10.
29. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946-2950. http://dx.doi.org/10.1128/AAC.00103-06.
30. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S. 2011. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 66:1594-1599. http://dx.doi.org/10.1093/jac/dkr169.
31. Ikonomidis A, Neou E, Gogou V, Vrioni G, Tsakris A, Pournaras S. 2009. Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii. J Clin Microbiol 47:4055-4059. http://dx.doi.org/10.1128/JCM.00959-09.
32. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 56:3086-3091. http://dx.doi.org/10.1128/AAC.06349-11.
33. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. 2015. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949-1956. http://dx.doi.org/10.1016/S0140-6736 (14) 62220-0.
34. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum (3-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57:1577-1582. http://dx.doi.org/10.1128/AAC.01590-12.
35. Livermore DM. 1993. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 31(Suppl A):9-21.
36. Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN. 1994. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and-susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother 38:2351-2356. http://dx.doi.org/10.1128/AAC.38.10.2351.
37. VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2014. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother 58:6024-6031. http://dx.doi.org/10.1128/AAC.02310-13.